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Background 
Mother-to-child transmission of HIV infection is the primary cause of paediatric 
HIV infections worldwide. High HIV infection rates in women of childbearing age 
(15-49 years) and efficiency of PMTCT have resulted in the high rate of HIV 
incidence and prevalence in children of sub-Saharan Africa. The stark contrast in 
the success of PMTCT interventions between the western countries and less 
developed countries indicates the need for further research to develop 
alternative, easier, and more effective population-based interventions.  
 
Methodology 
This was a retrospective cohort study of the medical records of approximately 
300 HIV infected women enrolled in the Nevirapine Resistance study between 
May 2002 and February 2003. An assessment of the significance of changes in 
immunological parameters (CD4 counts, CD4 percentages, CD4/CD8 ratios) and 
HIV RNA from 3rd trimester to 6 weeks postpartum and causal associations 
 vi 
between these changes and increased risk of PMTCT was then conducted using 
logistic regression models.  
 
Results 
Mothers with CD4 counts above 200cells/µL were approximately exhibited one-
third the likelihood of transmitting HIV-1 to their infants than mothers with CD4 
counts below 200 cells/µL [OR 0.35 (0.13, 0.95)]. High maternal HIV RNA levels 
demonstrated a stronger association with increased risk of PMTCT with women 
with postpartum viral loads greater than 100 000 copies/µL exhibiting ten times 
the likelihood [OR 10.15 (2.17-47.55)]. Statistically significant mean increases in 
CD4 and CD8 cell counts from 3rd trimester to postpartum were observed. Mean 
increases in CD4 and CD8 counts demonstrated no association with PMTCT. 
 
 
Conclusion 
CD4 cell counts and CD8 cell counts underwent statistically significant changes 
from 3rd trimester to postpartum. These changes seem not to represent any 
clinically significant change in maternal disease progression during this time 
period and were found not to be associated with PMTCT. 
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CHAPTER 1 
INTRODUCTION 
 
UNAIDS estimates of HIV prevalence in 2005 indicated that 24.5 million of the 
38.6 million people infected with HIV were living in sub-Saharan Africa, 75 
percent of which were women age 15 years and older (UNAIDS, 2006). During 
the same year, it was estimated that there were 540 000 new paediatric HIV 
infections worldwide and mother-to-child HIV transmission (PMTCT) accounts for 
more than 95 percent of the childhood paediatric HIV infections in sub-Saharan 
Africa (Handbook on Paediatric AIDS in Africa, 2006). High HIV infection rates in 
women of childbearing age (15-49 years) and efficiency of PMTCT of HIV have 
resulted in the high incidence and prevalence of HIV in children in sub-Saharan 
Africa. In the absence of appropriate PMTCT interventions, the risk of an HIV 
infected mother transmitting HIV to her infant is between 30-40 percent (De Cock 
et al, 2000).   
 
Mother-to-child transmission of HIV is the primary cause of paediatric HIV 
infections worldwide. Although clinical trials show that antiretroviral therapy, 
elective caesarean section and formula feeding can significantly reduce the 
peripartum or postpartum risk of transmission (Fowler 2000; Scarlatti 2004; 
UNAIDS 2004), their application on a population basis has achieved mixed 
success and continues to be a challenge. In industrialized countries, Perinatal 
Mother to Child Transmission of HIV (PMTCT) interventions are widely used and 
have become routine resulting in PMTCT transmission rates of less than 2 
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percent (Handbook on Paediatric AIDS in Africa, 2006). In less developed 
countries, limited resources and poor infrastructure have resulted in the lack of or 
partial implementation of PMTCT prevention interventions and have impeded 
uptake of PMTCT services by HIV infected mothers, significantly limiting the 
reach and scope of these proven PMTCT interventions. The WHO reports that 
only 11 percent of HIV-positive pregnant women in low and middle-income 
countries had access to services for preventing PMTCT in 2006 (WHO progress 
report on Universal Access to Care, 2006).  
 
The widespread use and the low rate of PMTCT in industrialized countries 
provides evidence that the transmission of HIV infection from mother to child is 
preventable. The challenges that impede implementation of proven PMTCT 
strategies in Africa have resulted in the greatest burden of disease due to 
PMTCT existing in those parts of the world most in need. Therefore, additional 
research is required to develop simple and affordable prevention strategies if the 
global incidence of paediatric HIV infection is to be significantly reduced.  
 
1.1 BACKGROUND ON PMTCT 
Over 95 percent of HIV infected infants in Africa contract the virus from their 
mothers during pregnancy, labour and delivery or through breastfeeding 
(Handbook on Paediatric AIDS in Africa, 2004). The risk of HIV transmission from 
mother to child is 15-20 percent during pregnancy; 50 percent during labour and 
delivery, and between 30-40 percent during breastfeeding (Mofenson et al., 
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1999; UNICEF 2002). Without the intervention of antiretroviral therapy, the risk of 
MTCT is estimated to be 15-20 percent in Europe, 15-30 percent in USA and 25-
30 percent in Africa (Working Group on MTCT of HIV, 1995). However,  
Numerous maternal and infant risk factors are associated with MTCT. Maternal 
risk factors include high viral load, severe immunosuppression (low CD4 cell 
counts), advanced disease, obstetrical complications and mode of delivery 
(Levine, 1999; Mofenson et al., 1999; Zijenah et al., Italian Collaborative Study 
on HIV infection, 1999; McGowan et al. European Collaborative Study, 1992). 
Infant risk factors include premature birth, breast-feeding, invasive fetal 
monitoring and prolonged rupture of membranes during delivery and twin 
pregnancies. Low maternal CD4 counts and high maternal HIV RNA levels have 
been identified as the major determinants of increased risk of MTCT (Mofenson 
et al., 1999; Zijenah et al., Italian Collaborative Study on HIV infection, 1999). 
 
1.2 HIV, PREGNANCY & PMTCT 
Pregnancy, in and of itself, has been shown not to be associated with an 
increased risk of HIV disease progression. Several studies have also revealed no 
significant differences in obstetric outcomes between HIV infected and uninfected 
mothers. However, obstetric complications have been shown to be associated 
with an increased risk of PMTCT.  An early study on a cohort of 525 mother-
infant pairs enrolled in the Woman and Infant Transmission study (WITS) 
demonstrated an independent association between maternal factors (low 
gestational age (<27 weeks), low mean CD4 cell counts (<29%) and high mean 
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CD8 cell counts (>50%) during pregnancy, prolonged rupture of membranes 
(>4hours) and presence of chorioamnionitis at delivery) and PMTCT in HIV 
infected mothers (Landesman et al., 1996). Preterm birth and low birth-weight 
(<2 500g) were the infant factors found to be independently associated with HIV 
in the same study. Logistic regression analysis of the observed independent risk 
factors for PMTCT revealed that prolonged rupture of membranes (>4hrs) 
(adjusted odds ratio, 1.82; 95%, 1.10-3.00), low mean CD4 cell counts (adjusted 
odds ratio,2.82; 95% CI, 1.67-4.76) and low birth weight (adjusted odds 
ratio=1.86; 95% CI, 1.03-3.34) were the infant and maternal obstetric factors 
associated with an increased risk of PMTCT (Landesman et al., 1996).  
 
The study by Landesman rightly identified obstetric factors independently 
associated with an increased risk in PMTCT, however, certain features of the 
methodology and analysis inadvertently led to inaccurate and incomplete 
findings. Women qualified for enrollment in the WITS study if entered the study at 
any stage during pregnancy and were available for follow-up at least seven days 
after birth. HIV RNA (viral load) measurements were also not collected. High viral 
loads have been identified to be the primary predictor of PMTCT. Viral loads 
have been demonstrated to remain relatively stable throughout the course of 
pregnancy, barring the introduction or change in antiretroviral therapy (Fang et 
al., 1995). The omission of viral load measurements in the Landesman study 
means that the adjusted odds ratios indicated in the findings are most likely 
overestimations of the predictive value of these factors on increased risk of 
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PMTCT. Subsequent studies of the same cohort of HIV infected mothers 
investigating the association between obstetric and immunologic factors, viral 
loads and the risk of PMTCT have shown that though obstetric factors are 
independently associated with PMTCT, viral load is the main predictor of PMTCT 
(Fang et al., 1995; Kreitchmann et al., 2004., Mofenson et al., 1999; Sperling et 
al., 1996). Mofenson et al. (1999) further examined the predictive value of the 
various maternal obstetric factors, CD4 cell counts (per 100 cell decrement), HIV 
titer (per log decrement), viral loads (per log decrement) and HIV p-24 antibody 
(per log decrement) by collecting measurements at baseline (20-30 weeks) and 
delivery. The measurements were fitted into univariate and multivariate models 
based on the time-point at which they were collected. Review of the models, 
including those controlling for all covariates, showed that high viral load at 
delivery was the strongest predictor of PMTCT (unadjusted odds ratio, 4.1; 95% 
CI, 2.2-7.6).  
  
1.3 LYMPHOCYTE CELL COUNTS, PREGNANCY & HIV 
The immune system comprises of groups of specialized cells (lymphocytes) that 
fight off infection and prevent the onset of illness. T lymphocytes (“CD4 cells”) 
identify the presence of germs in the body and initiate the immune response to 
prevent the onset of illness. HIV targets the CD4 cells: it enters the CD4 cell 
through binding to CD4 receptors, utilizes the cell’s nuclear mechanisms to 
replicate itself—through integration with the cell’s DNA and ultimately leads to 
cell death.   
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The pathogenesis of HIV infection is largely attributable to CD4 cell depletion and 
dysfunction. HIV-related immunodeficiency is assessed and defined by 
measuring the absolute CD4 count (total count of CD4 cells in peripheral blood) 
or CD4 percentage (percentage of lymphocyte cells in peripheral blood that are 
CD4 cells). The progressive depletion of CD4 cells is associated with progression 
of HIV disease and an increased likelihood of HIV-related clinical events. 
Absolute CD4 counts and, less so, percentage of CD4 cells fluctuate within an 
individual and depend on intercurrent illness, physiological changes or test 
variability. In a double cohort study of untreated HIV-positive adults, higher HIV 
RNA levels were found to be associated with an increase in the average rate of 
decline in CD4 cell counts Rodriguez et al. (2006). Average CD4 cell count 
decline was consistently greater with higher presenting HIV RNA levels, ranging 
from 20 cells per year in the less than 500 copies/mL stratum (95% CI, 9-31 cells 
per year; n=176) to 78 cells per year (95% CI, 68-87 cells per year; n=330) in the 
greater than 40 000 copies/mL stratum. 
 
Studies that have embarked on elaborating the changes in CD4 cell counts 
throughout the course of a pregnancy in both HIV infected and uninfected women 
have produced contradictory reports. Several studies have shown that, despite 
undergoing temporal changes, CD4+, CD8+ cell counts and CD4/CD8 ratios do 
not change significantly throughout the course of a pregnancy (Kühnert et al., 
1998; van Benthem et al., 2002). Some studies have also shown that differences 
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in trends of lymphocyte cell counts between HIV infected and uninfected women 
to not be statistically significant (Miotti et al., 1992; Tuomala et al., 1997). 
However, others have shown that CD4+ cell counts steadily decline during 
normal pregnancy and postpartum, with a marked decline in HIV-infected 
pregnant women (Biggar et al., 1989; Burns et al., 1996; Castilla et al., 1989); 
CD8+ cell counts increase from third trimester to early postpartum before 
returning to baseline levels (Burns et al., 1996; Ibrahim et al., 2004).  
 
The conflicting findings from these studies may be partially due to methodological 
differences, in particular whether the CD4+ and CD8+ parameters were assessed 
as absolute/mean counts or as percentages/proportions of the total number of 
white blood cells present in the blood (Biggar et al., 1989; Kühnert et al., 1998). 
These differences may also have been due to physiological changes that occur 
during pregnancy (Miotti et al., 1992)] and increased blood levels of reproductive 
hormones, namely progesterone and estrodial (van Benthem et al., 2002) have 
been reported to decrease the levels of CD4+ and CD8+ cells in pregnant women.  
 
In a cross-sectional study, Ibrahim et al. investigated cellular immunological 
changes during pregnancy and postpartum in HIV infected and non-infected 
pregnant women. The sample size comprised of 86 HIV infected and 152 
uninfected pregnant women. In line with similar investigations, Ibrahim et al. 
found that lymphocyte fluctuations during pregnancy to not be statistically 
significant, within the groups, though lymphocyte levels across the groups were 
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significantly different. However, the CD4 counts and CD8 counts in the HIV 
infected women were observed to undergo statistically significant increases from 
third trimester (>28 weeks) to postpartum (< 1 week after delivery).  
 
Numerous studies have demonstrated that HIV RNA levels and lymphocyte cells 
undergo a varying degree of changes during pregnancy. However, few studies 
have investigated the association between these changes and PMTCT. The 
finding, by Ibrahim et al., hints at the possibility that changes in lymphocyte cells 
play a functional role in PMTCT.  
 
This study aims to assess the immunological changes from 3rd trimester to early 
postpartum and investigate if there exists a causal association between the 
immunological changes and an increased risk of PMTCT.  
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CHAPTER 2 
STUDY AIMS 
The aim of this study was to investigate the magnitude of the changes in 
maternal lymphocyte subpopulations from third trimester to 6 weeks postpartum. 
In addition, this study was intended to investigate if the changes in lymphocyte 
cell levels—in their role as indicators of maternal disease progression—in HIV+ 
mothers may better elucidate the association between maternal 
immunocompetency during late pregnancy and intrapartum mother-to-child HIV-1 
transmission. 
 
2.1 RESEARCH HYPOTHESIS 
Changes in lymphocyte subsets from late pregnancy to early postpartum are 
associated with the increased risk of PMTCT. 
 
2.2 STUDY OBJECTIVES 
 
2.2.1 GENERAL OBJECTIVES 
To study the changes in lymphocyte subset levels in HIV-1 infected mothers 
from third trimester to early postpartum and evaluate the effect they have on 
the risk of PMTCT.  
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2.2.2 SPECIFIC OBJECTIVES 
Regarding HIV seropositive mothers seeking antenatal care (ANC) at Chris 
Hani Baragwanath Hospital (CHBH) and giving birth during September 
2002-September 2003, to: 
1. Determine the incidence of HIV-1 in the infants included in the cohort. 
2. Assess the association between lymphocyte levels at 3rd trimester and 
early postpartum and the incidence of HIV-1 in infants born to mothers 
in the cohort. 
3. Assess the association between HIV-1 transmission rates and low 
baseline CD4+ cell counts. 
4. Evaluate the association between the rate of change in lymphocyte 
levels from 3rd trimester to postpartum and PMTCT. 
5. Fit regression models to determine the value of 3rd trimester and 
postpartum lymphocyte measurements as predictors of risk of PMTCT 
should significant associations between lymphocyte subsets and 
PMTCT be determined.   
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CHAPTER 3 
METHODOLOGY 
3.1  STUDY DESIGN 
This was a retrospective cohort study of medical records of approximately 300 
HIV-positive pregnant women who participated in the Nevirapine Resistance 
study.  
 
3.2 VARIABLES OF INTEREST 
 Infant date of birth 
 Infant HIV status 
 Maternal HIV status 
 Maternal lymphocyte measurements (CD4, CD8, CD4% and CD4/CD8 
ratio) at 3rd trimester and postpartum 
 Maternal viral load measurements at 3rd trimester and postpartum 
 Method of infant feeding 
 Mother and infant antiretroviral history 
 Mode of delivery 
(NB: Postpartum values refer to measurements taken at the follow-up visit) 
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3.3 INCLUSION CRITERIA 
 Infant HIV status must have been ascertained by DNA PCR at 6-8 
weeks postpartum 
 Mother-infant pair must have known antiretroviral history (i.e. type of 
antiretrovirals administered, if any, and duration of treatment. 
 
3.4 EXCLUSION CRITERIA 
All mother-infant pairs that do not meet all of the inclusion criteria will be 
excluded from study analysis. 
 
3.5 THE NEVIRAPINE RESISTANCE STUDY 
The NVPR study investigated whether an intrapartum dose of NVP selects NVP-
resistant strains of HIV-1 in infected mothers and their infants, and to try and 
determine the how long these resistant strains remained detectable (McIntyre et 
al., 2002). The participating women were recruited from operational research 
pilot sites, namely CHBH in Johannesburg and King Edward Hospital in Durban, 
and enrolled into the study during May 2002 to February 2003. Women who had 
provided written informed consent were enrolled into the study. Blood samples 
were obtained from the mothers prior to birth and administration of a single dose 
of NVP; and from both the mothers and their infants at 6 weeks postpartum, 6 
months, 1 year and 18 months. These samples were analyzed by the National 
Institute for Communicable Diseases to verify the presence and persistence of 
NVP-resistant viral strains as well as to determine the key immunological and 
virological parameters, in particular lymphocyte subsets and viral load.  
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3.6 STUDY POPULATION 
The study population comprised of women enrolled in the NVPR study during an 
antenatal visit, late in pregnancy, and returned for follow up visits after giving 
birth. In the study population used for this particular analysis, there were 397 
HIV-positive pregnant women who initially gave their consent during their 
antenatal visit and were consequently enrolled into the study cohort for the NVPR 
study. However, there were only approximately 304 women who returned for 
their scheduled follow-up visit at 6 weeks postpartum. A primary analysis shall be 
conducted on the available data of the enrolled participants.  
 
3.7 SAMPLE SIZE 
The process of calculating an adequate sample size requires the quantification of 
the study objectives. To achieve this required sample size, it is necessary to take 
into consideration strength of evidence required to reject the null hypothesis (p-
value), and the probability of achieving a desired level of significance (Kirkwood 
& Sterne, 2004). The values of the mean changes in CD4 and CD8 cell counts 
from 3rd trimester to postpartum are based on the findings the study by Ibrahim et 
al.  
The sample size was calculated using STATA 8.0. Type I error was set at 
α=0.05, the type II (β) at 0.10 and the power of the study (1-β) =0.90. STATA 
output of the sample size calculation are illustrated in Appendix 1. The sample of 
304 mothers was found to be more than adequate to satisfy the requirements of 
having a 90% power of demonstrating a statistically significant association 
between the mean changes in CD4+ cell counts from 3rd trimester to postpartum.   
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3.8 DATA MANAGEMENT 
All the variables used in this study, except for CD4 percentages and CD8 cell 
counts, were attained electronically from PHRU and the NIV virology lab in 
Microsoft Access format. The information on the CD4 percentages and the CD8 
cell counts was entered manually from the original patient files. The data was 
then transferred into Stata 8.2 (StataCorp; College Station, Texas, U.S.A) using 
Stattransfer 7 (Circle Systems; Seattle, Washington U.S.A) for the data 
management and analysis stages of this study.  
 
A total of 397 HIV-1 positive mothers enrolled in the study. Of these initial 
participants, 396 (99.7%) had CD4 counts and CD4/CD8 ratios, 383 (96.5%) had 
CD4 percentages and CD8 counts, while 397 (100%) had viral load 
measurements. 304 (76.6%) mothers returned for the follow-up visit at 6 weeks 
postpartum. CD4 counts, CD4/CD8 ratios and viral load measurements, at both 
the enrollment and follow-up visits, were recorded for 301(75.8%) of the total 
number of women enrolled in the study. CD8 counts and CD4 percentages were 
only recorded at both time points for 271 (68.3%) of the mother’s who had initially 
enrolled into the study. The primary analysis was based on the population of 
women who had returned for the follow-up visit. The number of infants born into 
the cohort was 316, of which 313 (99.4%) had DNA PCR results.  
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3.9 ETHICAL CONSIDERATIONS 
The study was conducted in accordance with the stipulated guidelines on 
medical research involving human subjects of the University of the 
Witwatersrand. The research protocol for this study was approved by the 
Protocol Research Committee of PHRU, the Postgraduate Committee of the 
University of the Witwatersrand and Committee for Research on Human Subjects 
(medical), of the University of the Witwatersrand. Permission to access and 
utilize the data was sought from the Perinatal Health Research Unit (PHRU) at 
Chris Hani Baragwanath Hospital. The dataset did not contain any personal 
information about the participants that was not pertinent to the objectives of this 
particular study. Informed consent for the use of the data for the purposes of this 
study was not sought directly from the members of the cohort from whom this 
data was originally obtained. However, written informed consent was a 
requirement for all participants who enrolled in the original study conducted by 
PHRU. The results of the study shall be made available to the general public by 
submitting copies of the report to the Wits Health Sciences Library and Perinatal 
Health Research Unit. In addition efforts will be made to publish the findings in a 
medical journal. 
 
 
3.10 DATA ANALYSIS 
Normal plots were used to assess the distribution of CD4 & CD8 cell counts, CD4 
percentages, CD4/CD8 ratios. CD4 counts and CD4/CD8 ratios had a slightly 
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positively skewed distribution with heavy tails at the higher values. CD8 counts 
had an irregular distribution that roughly resembled a normal distribution at the 
lower values but then flattened out at values above 1250 cells/µL and peaked 
abruptly at 2000 cells/µL. The peak at the higher end of the distribution was due 
to the fact that the highest calibrated measurement was 2000 cells/µL (Graphic 
representations of the distribution may be viewed in Appendix 2). In order to 
satisfy the assumptions of symmetrical distribution that the various statistical 
tests used in the analysis are based on, CD4 counts, CD8 counts and CD4/CD8 
ratios were square root transformed while the viral load measurements were 
log10 transformed. CD4 percentages demonstrated a normal distribution and so 
were not transformed. The results from the bivariate and multivariate analyses 
were similar with untransformed and transformed data. Hence the untransformed 
measurements were used for ease of interpretation and to keep the logistic 
models as parsimonious as possible, except for viral loads for which the log10 
transformed data was reported in the comparative analysis. 
 
Several of the variables of interest were categorized to facilitate analysis and 
interpretation of the results: CD4 counts were converted into a binary variable 
(<200, >200cells/mm3) as well as an ordered categorical variable (≤200, 201-
350, 351-500, >500cells/mm3); CD4 percentages were coded as ≤20%, >20%; 
CD8 cell counts were coded as ≤300, 301-650, 651-1000, >1000; CD4/CD8 
ratios were coded as <0.5, 0.5-1, >1.0-1.5, >1.5; viral loads coded as <10 000, 
10 000-100 000, >100 000 copies/mL.   
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 Univariate analysis was conducted to describe selected background and 
lymphocyte characteristics of the women at the 3rd trimester visit and postpartum 
(follow-up) time points. It was noted that there was a significant number of 
women who had returned for their first follow-up visit long after 6 weeks 
postpartum. Therefore prior to continuing with the analysis, the women were 
stratified into the following groups based on the length of time that elapsed 
between delivery and the follow-up visit: 3-6 weeks, 6-9 weeks, 9-12 weeks and 
12-37 weeks. One-way analysis of variance (ANOVA) with post hoc tests 
(Bonferroni, Sidak, Scheffe) were conducted to determine if the subgroups of 
mothers were intrinsically homogeneous, with regard to the characteristics under 
study, and thus could have been analyzed collectively. Univariate logistic models 
were fitted to assess the strength of association between perinatal HIV-1 
transmission and lymphocyte subset levels and identified confounders (viral load 
and obstetric factors).   
 
For the comparative analyses, paired-sample t-tests were conducted to 
determine the significance of the differences between 3rd trimester and 
postpartum lymphocyte measurements. An overall rate of change of maternal 
CD4 counts for each mother was calculated as the quotient of the difference in 
3rd trimester and postpartum CD4 counts divided by time elapsed from delivery 
to the follow-up visit. This was then used to examine if there were significant 
differences in the rates of change in maternal CD4 counts between mothers 
depending on whether they transmitted HIV to their infants or not. Furthermore, 
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mothers were categorized into groups according to the week they returned for 
the follow-up visit and a mean difference in 3rd trimester-to-postpartum CD4 
counts was calculated for each group. This was done to compare the mean 
change in CD4 counts by maternal transmission status against the time elapsed 
from them giving birth to the follow-up visit.   
 
The maternal lymphocyte and background characteristics found to be 
significantly associated with infant HIV incidence were fitted in multivariate 
logistic regression models. Associations were regarded as significant if they had 
a P-value ≤0.05. The identified confounders of the association between CD4 
counts and MTCT were also included in the multivariate logistic regression 
models. The inclusion of confounders in the multivariate analyses was conducted 
to minimize the chances of attaining misleading estimates of effect that would 
lead to inaccurate causal inferences and conclusions (Beaglehole et. al., 2003).  
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CHAPTER 4 
RESULTS 
4.1 UNIVARIATE ANALYSIS 
A total of 316 live-born infants were born to mothers in the study, including 304 
singletons and 12 sets of twins. The records of one infant from a pair of twins 
were missing and hence this infant was not included in the analysis. For the 
purposes of analysis, the infants were treated as individuals, resulting in the 
double enumeration of mothers who had given birth to twins in the analyses that 
were conducted on mother-child pairs. Hence the analyses involving mother-child 
pairs were based on a sample of 315 mother-child pairs; the analyses of 
maternal lymphocyte changes were based on a sample of 304 mothers. Overall, 
28 infants were noted to have tested positive for HIV-1 at the follow-up period 
giving a PMTCT rate of 9.2% (95% CI: 6.2, 13). Two sets of twins were observed 
to have disconcordant DNA-PCR results. 
 
Table 4.1 illustrates the distribution of selected background characteristics of the 
mothers and infants in the study cohort. The mean gestational age of the 
mothers at enrollment was 36 weeks. Approximately all mothers (99.67%) were 
administered with ingested single-dose nevirapine during pregnancy and 1 
mother (0.33%) was received. A considerable number of the mothers were 
recorded to have ingested nevirapine more than once, with 7.6% having taken 
nevirapine twice and 1.64% having taken it three times. The proportions of 
mothers who had given birth through vaginal, caesarian and assisted delivery 
were 61.5%, 37.5% and 1% respectively. The predomin
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nutrition was formula feeding (92.11%), with 18% using a combination method 
consisting of breast-milk supplemented by formula and 5% providing nutrition to 
their infants solely through breastfeeding. All infants were given nevirapine at 
birth, but the administered dosage was confirmed by bed letter for only 284 
(90.16%) of these infants. Over 90% of the mothers in the cohort were reported 
to practice exclusive formula-feeding, with 5.92% and 1.64% of mothers 
practicing mixed-feeding and exclusive breast-feeding respectively.  
Table 4.1: Distribution of selected maternal and infant background characteristics 
and antiretroviral history. Values are expressed as n (%) or mean (SD). 
 
Characteristic      
Gestational Age at 
enrollment 
(weeks)     35.98 [2.90] 
      
Maternal antiretroviral history in current pregnancy  
Nevirapine (NVP)    303 [99.67] 
AZT    1[0.33] 
      
Single Dose NVP    273 [89.80] 
Double Dose NVP    23 [7.57] 
Triple Dose NVP    5 [1.64] 
Uncertain NVP history    3 [0.99] 
Mode of delivery      
Vaginal Delivery    187 [61.50] 
Caesarian    114 [37.50] 
Assisted Delivery    3 [1.00] 
      
Infant antiretroviral history     
Confirmed NVP dose    284 [90.16] 
Unconfirmed NVP dose    31 [9.84] 
      
Infant nutrition     
Breast-feeding only    5 [1.64] 
Brest-feeding/formula    18 [5.92] 
Formula-feeding only       280 [92.11] 
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A total of 304 (76.5%) women enrolled in the study returned for the follow-up visit 
at 6 weeks postpartum. The mean time at which the women returned for the 
follow-up visit was 9.8 weeks, ranging from 3.1 weeks to 37.1 weeks. The 
distribution of the length of time that elapsed before the mothers returned for the 
follow-up visit is represented in Figure 3.1. Approximately half (48.4%) of all 
mothers returned for the follow-up visit between 6-9 weeks postpartum; the 
remaining mothers reported for the follow-up visit at 3-6 weeks (20.1%), 9-12 
weeks (11.8%) and greater than 12 weeks (19.7%).  
 
20.07%
48.36%
11.84%
19.74%
3-6 weeks 6-9 weeks 9-12 weeks >12 weeks
Source: data from NVPR study
 
Figure 4.1: Percentage distribution of mothers by the length of time that elapsed 
from delivery to follow-up visit.  
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Given the unexpectedly wide range in the times at which the mothers reported for 
the follow-up visit, the mothers were stratified according to the time elapsed 
between delivery and when they reported for the follow-up visit. The results of the 
oneway analysis of variance (ANOVA) carried out to determine if the different 
subgroups of mothers differed with regard to any of the main variables of interest 
are shown in Table 3.2. The results show that there were no significant 
differences in the main maternal lymphocyte and viral characteristics under 
study, regardless of whether the mothers had presented themselves for their first 
check-up at 6 weeks postpartum, slightly earlier (<6 weeks) or much later (>12 
weeks). All groups were comparable with regards to the main variables of 
interest. 
 
Table 4.2 Comparison of maternal lymphocyte characteristics stratified by time 
the mothers returned for the follow-up visit. Values are expressed as mean [SD]. 
 
Variable (n) Time Elapsed Between Delivery & Postpartum Visit 
P-
Value* 
 3-6 weeks 6-9 weeks 9-12 weeks 12-37 weeks  
3
rd
 TRIMESTER      
CD4 cell counts (396) 436 [241] 448 [261] 399 [218] 487 [294] 0.42 
CD8 cell counts (383) 973 [364] 1008 [434] 1013 [478] 1094 [409] 0.46 
CD4% (383) 29.05 [12.59] 29.54 [12.10] 27.86 [13.89] 28.99 [12.74] 0.91 
CD4/CD8 Ratios (396) 0.49 [0.29] 0.49 [0.30] 0.48 [0.33] 0.48 [0.28] 0.10 
Square root CD4 cell counts (396)  0.67 [0.21] 0.66 [0.22] 0.65 [0.24] 0.66 [0.21] 0.96 
Square root CD8 cell counts (396) 30.60 [6.14] 31.03 [6.78] 31.00 [7.26] 35.54 [6.01] 0.39 
Log10 viral load (397) 4.34 [0.92] 4.28 [0.84] 4.49 [0.93] 4.33 [0.84] 0.63 
FOLLOW-UP      
CD4 cell counts (301) 545 [301] 605 [379] 498 [321] 506 [299] 0.16 
CD8 cell counts (271) 1356 [460] 1354 [487] 1249 [459] 1203 [423] 0.21 
CD4% (271) 27.16 [12.75] 28.67 [12.07] 27.23 [12.29] 25.33 [11.24] 0.43 
CD4/CD8 Ratios (301) 0.45 [0.30] 0.48 [0.32] 0.46 [0.30] 0.44 [0.26] 0.73 
Square root CD4 cell counts (301) 22.5 [6.27] 23.5 [7.3] 20.98 [7.79] 21.42 [6.9] 0.12 
Square root CD8 cell counts (301) 36.25 [6.57] 31.14 [6.99] 34.70 [6.81] 34.14 [6.18] 0.27 
Log10 viral load (301) 4.38 [0.87] 4.20 [0.84] 4.23 [0.87] 4.41 [0.84] 0.31 
*
p-value for trend 
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Table 4.3 shows the results of univariate logistic regression models that were 
fitted to test for the association between PMTCT and the following: lymphocyte 
subset levels, viral load, number of doses of NVP mothers ingested and whether 
or not mothers had Caesarian deliveries. CD4 counts, CD4/CD8 ratios, CD4 
percentages, Caesarian delivery and number of NVP tablets ingested were found 
not to be associated with PMTCT. A borderline, though statistically significant, 
association between postpartum CD4 counts and PMTCT was observed (95% CI 
0.13,0.95) . This analysis was repeated excluding the stratum of women who had 
returned for their first follow-up visit at 12 weeks or more and the strength of 
association was noted to increase to statistically significant levels (p=0.03). The 
unadjusted odds ratio [0.26; (95%CI: 0.09, 0.81)] for this group of women 
indicated that women who had postpartum (~6weeks) CD4 cell counts greater 
than 200 cells/µl were less than one-third times as likely to have transmitted HIV 
to their infants as women who had CD4 counts less than 200 cells/µl. No 
association between changes in CD4 counts from 3rd trimester to postpartum and 
MTCT (P=0.85) were observed. High maternal viral loads of greater than 100 000 
copies/ml at the pre-birth visit were 6.13 (95% CI: 1.69, 22.15) times more likely 
of transmitting HIV to their infants than mothers who had a viral load less than 10 
000 copies/mL. At the follow-up visit, mothers who had viral loads of between 10 
000-100 000 copies/mL and greater than 100 000 copies/mL were 5.33 (95% CI: 
1.18, 24.03) and 10.15 (95% CI: 2.17, 47.55) times more likely to transmit HIV to 
their infants, respectively, than mothers who had less than 10 000 copies/mL.      
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Table 4.3: Univariate analysis of variables of interest associated with mother-to-
child HIV-1 transmission.  
#Calculated as the change in from 3
rd
 trimester to postpartum. 
*
P-value for trend. 
†
Each infant in twin births 
was enumerated as an  individual birth. 
 
Variable   
HIV positive 
 mothers, n (%) 
HIV Transmitting  
Mothers, n (%) OR (95%CI) P- value 
3
rd
 TRIMESTER     
CD4 cell counts    0.34 
≤200  59 6 (10.17) 1  
>200  337 22 (6.53) 0.62 (0.24-1.59)  
CD4%     0.17 
≤20%  102 10 (9.80) 1  
>20%  281 16 (5.69) 0.56 (0.24-1.27)  
CD4/CD8 Ratios    0.71

 
<0.5  241 19 (7.88) 1  
0.5-1  132 8 (6.06) 0.75(0.32-1.77)  
>1-1.5  22 1 (4.55) 0.56 (0.07-4.37)  
>1.5  1 0 (0.00) N/A  
Viral Load (copies/mL)    0.001

 
<10 000   126 3 (2.38) 1  
10 000-100 000 171 12 (7.02) 3.09 (0.85-11.21)  
>100 000   100 13 (13.00) 6.13 (1.69-22.15)   
FOLLOW-UP     
CD4 cell counts    0.06 
≤200  31 6 (19.35) 1  
>200  270 21 (7.78) 0.35 (0.13-0.95)  
CD4%     0.15 
≤20%  78 9 (11.54) 1  
>20%  193 12 (6.22) 0.51 (0.21-1.26)  
CD4/CD8 Ratios    0.41

 
<0.5  187 20 (10.70) 1  
0.5-1  97 6 (6.19) 0.55 (0.21-1.42)  
>1-1.5  15 1 (6.67) 0.60 (0.07-4.78)  
>1.5  2 0 (0.00) N/A  
Viral Load     0.002

 
<10 000  98 2 (2.04) 1  
10 000-100 000 140 14 (10.00) 5.33(1.18-24.03)  
>100 000   63 11 (17.46) 10.15 (2.17-47.55)   
#Change in CD4 count   0.85 
Increase  71 7 (9.86) 1  
Decrease  231 21 (9.09) 0.91 (0.37-2.25)  
NVP doses taken    0.68 
Single  276 26 (9.42) 1  
Multiple  28 2 (7.14) 0.74 (0.17-3.29)  
†
Caesarian      
Yes  195 21 (10.77) 1 0.82 
No   120 8 (6.67) 0.91 (0.39-2.11)   
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Chi-squared analysis revealed significant association was found between 3rd 
trimester CD8 counts (χ2(3) =0.55, P=0.91), postpartum CD8 counts (χ
2
(1) =0.56, 
P=0.91) and PMTCT. A tabulated format of these results is presented in 
Appendix 3. 
 
4.2 BIVARIATE ANALYSIS 
Mothers who transmitted HIV-1 to their infants were noted to have had lower 
mean increases in CD4 and CD8 counts, while exhibiting higher mean decreases 
in CD4/CD8 ratios and CD4 percentages than their counterparts who did not 
transmit HIV-1 to their infants. However, the associations between MTCT and 
mean change in lymphocyte subsets (CD4 counts, CD8 counts, CD4/CD8 and 
CD4 percentages) were found to not be statistically significant.  The mean 
change in CD4 count was an increase of 49.59 cells/µl (95% CI: -3.40, 102.59) in 
transmitting mothers. In non-transmitting mothers, the absolute mean change in 
CD4 count was an increase of 119.56 cells/µl (95% CI: 93.10, 146.01). A graphic 
representation of the range and pattern of the changes in maternal CD4 counts 
from 3rd trimester to follow-up visit is illustrated in Appendix 4. The rate of change 
of CD4 counts in transmitting mothers was an average increase of 7.50 
cells/week (95% CI: 1.93, 13.06). In non-transmitting mothers, the overall rate of 
change in CD4 counts was an average increase of 17.06 cells/week (95% CI: 
13.22, 20.89). The mean increase in CD8 counts was 194.86 cells/µL (95% CI: 
5.51, 384.20) in transmitting and 301.24 cells/µL (95% CI: 250.46, 352.02). 
CD4/CD8 ratios decreased by an average of 0.05 (95% CI: 0.01, 0.04) and 0.02 
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(95% CI: 0.004, 0.04) for HIV-1 transmitting and non-transmitting mothers 
respectively. CD4 percentages decreased by 1.90% (95% CI: 0.26, 3.55) and 
1.24% (95% CI: 0.71, 1.78) for HIV-1 transmitting and non-transmitting mothers, 
respectively. Both groups of mothers demonstrated slight changes in the mean 
viral load of less than 1 log reduction:  an average log increase of 0.06 (95% CI: -
0.01, 0.12) amongst non-transmitting mothers and an average log reduction of 
0.18 (95% CI: -0.41, 0.4) amongst transmitting mothers. These results are 
illustrated in Table 4.4.  
 
Table 4.4: Comparisons of mean changes in lymphocyte subsets from 3rd 
trimester to postpartum in HIV-1 transmitting and non-transmitting mothers. 
Values given as mean [95% CI] 
 
Non-transmitting mothers  
(287) 
Transmitting mothers  
(28) 
†
CD4
 
119.56 
[93.10,146.01] 
49.59 
[-3.40,102.59] 
CD8 
301.24 
[250.46,352.02] 
194.86 
[5.51,384.20] 
†
CD4/CD8 
0.02 
[-0.04,-0.004] 
0.05 
[-0.04,-0.01] 
†
CD4% 
-1.24 
[-1.78,-0.71] 
-1.90 
[-3.55,-0.26] 
†
Viral Load (log10) 
0.06 
[-0.01,0.12] 
-0.18 
[-0.41,0.4] 
†
Negative values indicate a decrease in viral load/lymphocyte subset measurement from 3
rd
 trimester to first 
follow-up. 
 
Further examination of the mean differences in 3rd trimester and follow-up visit 
CD4 counts was conducted across groups of mothers who were categorized 
according to the week they returned for their first follow-up visit. The results 
(shown in Appendix 5) illustrate trends toward the gradual diminish in the 
magnitude of the difference between the 3rd trimester and follow-up visit CD4 
counts for both HIV-1 transmitting and non-transmitting mothers. In the case of 
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non-transmitting, it is evident that mothers who returned for the follow-up visit 
between 3 to 12 weeks postpartum experienced an increase in CD4 counts 
during this period with slight fluctuations from week-to-week. The week-to-week 
fluctuations in CD4 counts vary irregularly in mothers that returned for the follow-
up visit after 12 or more weeks.  
 
4.3 COMPARATIVE ANALYSIS 
Table 3.5 illustrates the results of the comparative analyses of the differences in 
the mean 3rd trimester and postpartum viral load and lymphocyte subset levels. 
The increase in mean maternal CD4 and CD8 counts from 3rd trimester to 
postpartum was noted to be statistically significant (P<0.001). The mean 
maternal CD4 counts at 3rd trimester and postpartum were 372.98 cells/µL (95% 
CI: 344.76, 403.49) and 460.36 cells/µL (95% CI: 427.27, 499.53), respectively. 
The mean maternal CD8 count at 3rd trimester was 933.89 cells/µL (95% CI: 
884.90, 985.60) and the mean maternal CD8 count at postpartum was 1223.85 
cells/µL (1164.92, 1285.76). The mean increase in CD4 counts during the time 
points of interest was 113.28 cells/µL (95% CI: 88.70-137.87). The average 
increase in CD8 counts was 292.94 cells/µL (95% CI: 244.08-341.79).  
 
Maternal CD4/CD8 ratios underwent a slight decrease from 0.40 (95% CI: 0.37, 
0.43) at 3rd trimester to 0.38 (0.35-0.41) at postpartum. Maternal CD4 
percentages decreased from 28.87% (95% CI: 27.38, 30.37) at 3rd trimester to 
27.62% (95% CI: 26.16, 29.08).  
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Viral loads also exhibited a slight decrease from a log10 count of 4.32 (95% CI: 
4.22, 4.42) at 3rd trimester to 4.28 (95% CI: 4.18, 4.38) at postpartum. The paired 
sample t-test analysis of viral loads revealed that this change in mean log viral 
load was not significant (P=0.259). The results of these paired-sample t-tests are 
illustrated in Table 4.5. 
 
Table 4.5: Comparison of 3rd trimester and postpartum viral load and lymphocyte 
subset levels. Values given as geometric mean [95% CI], except where indicated. 
 
Variable 
sample 
size (n) 3
rd
 trimester Postpartum P value
 
CD4 (cells/µl) 301 
372.98 
[344.76-403.49] 
460.36 
[427.27-499.53] <0.000 
CD8 (cells/µl) 267 
933.89 
[884.90-985.60] 
1223.85 
[1164.92-1285.76] <0.000 
CD4/CD8 ratio 301 
0.40 
[0.37-0.43] 
0.38 
[0.35-0.41] 0.004 
†
CD4% 267 
28.87 
[27.38-30.37] 
27.62 
[26.16-29.08] <0.000 
Viral load (log10) 301 4.32 [4.22-4.42] 4.28 [4.18-4.38] 0.259 
†
Means for CD4% given as arithmetic means.  
 
4.4 MULTIVARIATE ANALYSIS 
The final objective was to carry out a multivariate analysis to measure the 
strength of association between lymphocyte subsets and PMTCT, taking into 
account identified confounding factors. In this study, postpartum CD4 count was 
the only primary variable of interest found to demonstrate a significant 
association (P=0.04) with PMTCT. Third trimester and postpartum viral loads 
also exhibited a strong association with PMTCT and were incorporated into 
multiple regression models. Factors such as mode of delivery and number of 
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NVP doses ingested by the mothers, which were identified as potential 
confounders in this study were found not to exhibit statistically significant 
associations in the univariate model and were thus excluded from the 
multivariate analysis.  Hence the multivariate logistic regression models that were 
conducted included 3rd trimester and postpartum viral loads and postpartum CD4 
counts. To avoid complications of colinearity, 3rd trimester and postpartum viral 
loads were not included in the same model. Two separate models were fitted: 
one incorporating postpartum CD4 counts and baseline viral load, the other 
incorporating postpartum CD4 counts and postpartum viral load. Viral load was 
the only variable found to remain significant in both multiple regression models. 
In the univariate models, women with postpartum CD4 cell counts greater than 
200 cells/µL seemed to be less likely to transmit HIV-1 to their infants than those 
with postpartum CD4 cell counts less than 200 cells/µL (OR: 0.35, P=0.04). The 
protective effect of having a postpartum CD4 count of greater than 200 cells/µL  
was no longer significant (AOR: 0.59, P=0.33) after the inclusion of baseline viral 
load into the model. Similarly, having a postpartum CD4 count greater than 200 
cells/µL was also found not to be significant (AOR: 0.60, P=0.37) in the model 
incorporating postpartum viral load. These results are represented in Tables 4.6a 
and 4.6b.   
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Table 4.6a: Logistic Regression Model: Value of Maternal Postpartum CD4 Count 
& Baseline Viral Load as Predictors of PMTCT.  
  
 
 
 
 
 
 
 
∗Odds Ratio (95% Confidence Interval) P value. 
 
 
Table 4.6b: Logistic Regression Model: Values of Maternal Postpartum CD4 Count 
& Postpartum Viral Load as Predictors of PMTCT. 
∗Odds Ratio (95% Confidence Interval) P value. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Unadjusted Model Adjusted Model 
Postpartum CD4 count 
(cells/µL) 
 
 
≤200 1.00 1.00 
>200 0.35 (0.13-0.95) 0.04
∗ 0.59 (0.20-1.70) 0.33∗ 
Baseline viral load 
(copies/mL) 
 
 
<10 000 1.00 1.00 
10 000-100 000 3.09 (0.85-11.21) 0.09
∗ 2.79 (0.76-10.23) 0.12∗ 
>100 000 6.13 (1.69-22.15) 0.01
∗ 5.90 (1.52- 22.86) 0.01∗ 
Variable  Unadjusted Model Adjusted Model 
Postpartum CD4 count 
(cells/µL) 
 
 
≤200 1.00 1.00 
>200 0.35 (0.13-0.95) 0.04
∗ 0.60 (0.20-1.82) 0.37∗ 
Postpartum viral load 
(copies/mL) 
 
 
<10 000 1.00 1.00 
10 000-100 000 3.09 (0.85-11.21) 0.09
∗ 5.21 (1.16-23.54) 0.32∗ 
>100 000 6.13 (1.69-22.15) 0.01
∗ 8.54 (1.73- 42.26) 0.009∗ 
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CHAPTER 5 
DISCUSSION & CONCLUSION 
 
5.1 DISCUSSION 
This study was conducted to determine the significance of the changes in 
lymphocyte cell levels from 3rd trimester to postpartum and to examine the 
association between these changes and PMTCT. CD4 cell counts and CD8 cell 
counts were found to have undergone statistically significant changes from 3rd 
trimester to postpartum (~10 weeks). However, changes in other lymphocyte 
characteristics, namely CD4/CD8 ratios and CD4 percentages, were observed to 
not have undergone statistically significant changes during the same time period. 
Furthermore, despite the changes in CD4 and CD8 cell counts being of statistical 
significance, they remained within the same clinical ranges. 
 
The oneway ANOVA was primarily conducted to determine if the discrepancies in 
the time it took the mothers to report back to the clinic represented intrinsic 
differences between the mothers with regard to the variables of interest. This 
analysis was carried out to ascertain that the mean lymphocytic and viral 
characteristics across all subgroups of mothers were not significantly different 
from each other and thus the study population of mothers could be analyzed 
collectively without leading to erroneous conclusions. However, the fact that a 
good proportion of mothers who were included in the analysis had postpartum 
measurements were taken at time points significantly later than 6 weeks 
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postpartum means that the results of the comparative analysis, though valid, may 
not precisely represent the differences between the time points under study. 
Comparative analyses were repeated to assess the significance of the 
differences in mean 3rd trimester and postpartum lymphocyte characteristics of 
for each subgroup of mothers separately, depending on when the mothers had 
returned for their first follow-up visit. The results of these stratum-specific t-tests 
revealed similar results to those given by the analysis of the mothers as a 
collective group. The only exception was the comparative analysis of the CD4 
counts in the mothers who returned for their postpartum check-up after more 
than 12 weeks, which indicated a lack of significance between 3rd trimester and 
postpartum CD4 counts. 
 
The possibility that the longer the women stayed without reporting for their first 
follow-up may increase the chances they might transmit HIV to their infants 
through feeding was not an issue in this study because over 90% of the mothers 
predominantly formula-fed. No mothers who predominantly breastfed throughout 
the duration of the study period transmitted HIV to their infants.    
 
The sets of twins born into the cohort were treated as individuals in this study. 
This resulted in the double enumeration of the mothers who had given birth to 
twins in the analyses that were conducted on mother-child pairs. The 
enumeration of each member of a set of twins as an individual was due to the 
observation that there were two sets of twins in which the infants in each set had 
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misconcordant DNA-PCR results. Thus it was not feasible to analyze these twins 
collectively. However, the double enumeration of the mothers also brings forth 
alternate complications, particularly with regards to how the association between 
maternal characteristics and perinatal HIV-1 may be interpreted. On the other 
hand, each mother was enumerated only once in the comparative analysis of the 
differences between 3rd trimester and postpartum maternal characteristics since 
this analysis did not require linking maternal characteristics with those of the 
infants. 
 
The univariate logistic regression analysis and the bivariate analysis 
demonstrated that maternal viral load was strongly associated with PMTCT, as 
has been reported by Fang et al., 1995; Kreitchmann et al., 2004; Mofenson et 
al.,1999; and  Sperling et al., 1996. The univariate logistic model demonstrated 
an association between postpartum CD4 cell counts and PMTCT. However, no 
statistically significant association was observed between CD4 %, CD8 cell 
counts, CD4/CD8 ratios and 3rd trimester CD4 counts and PMTCT. The results 
for univariate logistic regression for CD8 counts, in particular those at first follow-
up, resulted in extremely large and nonsensical odds ratios and confidence 
intervals. This was probably due to the fact that the instrument used in the assay 
of the CD8 lymphocyte levels seemed to have been calibrated to a maximum 
reading of 2000 cells/µl. This resulted in several mothers [23 (8.55%) at 3rd 
trimester; 40 (14.29%) at first follow-up] being classified as having CD8 count of 
2000 cells/µl when in fact their CD8 counts could have been greater than 2000 
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cells/µl. This resulted in a distorted distribution of CD8 counts that followed the 
general pattern of a normal distribution but flattened out at the higher values and 
peaked drastically at 2000cells/µl. Graphic representation of this may be viewed 
in Appendix 2.  
 
The univariate model also showed that HIV-positive mothers, on single-dose 
nevirapine treatment, with CD4 cell counts greater than 200 cells/µl were 
approximately one-third as likely (Unadjusted Odds ratio=0.35) to transmit HIV to 
their infants than mothers with CD4 cell counts less than 200 cells/µl. This finding 
questions the effectiveness of administering single-dose nevirapine treatment to 
severely immunodepressed pregnant mothers during labor.  
 
In terms of the predicting the likelihood of an HIV positive mother transmitting 
HIV to her child during pregnancy and delivery, however, these multivariate 
logistic regression models demonstrated that maternal viral load is still a more 
significant and accurate predictor of MTCT than CD4 count.  
 
The mean changes in CD4 and CD8 cell counts demonstrated statistically 
significant increases from 3rd trimester to postpartum. These results are in 
agreement with previous studies that suggested that CD4 levels are elevated at 
postpartum in comparison to 3rd trimester (Burns et al., 1996), and that CD4, CD8 
cell counts at 3rd trimester and 1 week postpartum are significantly different from 
each other (Ibrahim et al., 2004). 
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The mean changes in CD4/CD8 ratios and CD4 percentages were noted to 
decrease from 3rd trimester to postpartum, but this decline was found to not be 
statistically significant. The p-values (Pr<0.05) for the paired t-tests of CD4 
percentages and CD4/CD8 ratios hinted at the possibility that the mean 
CD4/CD8 ratios and CD4 percentages at each time point were significantly 
different. However, the confidence intervals for both variables were noted to 
highly overlap. Hence the differences in the mean 3rd trimester and postpartum 
CD4/CD8 ratios and CD4 percentages were actually not statistically significant.  
 
5.2 STRENGTHS & WEAKNESSES 
Despite the revelation of statistically significant changes in CD4 and CD8 cell 
counts, it is still not clear from this study if such changes have any clinical 
significance. The mean CD8 cell count in this cohort of mothers, at both 3rd 
trimester and postpartum, was found to either be well within or above the 
established normal limits of 300-1000 cell/µl (Highleyman, 2003). Similarly, the 
mean CD4 cell counts at both time points of interest were well above the lower 
limit of normality for CD4 cell counts, which has been reported to extend well 
below 250 cells/µl in Sub-Saharan Africa (Gomo et al., 2004). Hence despite the 
mothers exhibiting statistically significant differences in 3rd trimester and 
postpartum CD4 and CD8 cell counts, these differences do not translate into 
mothers being at clinically different states of well-being.   
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The ambiguity of the clinical implications of the changes in CD4 and CD8 cell 
counts, despite statistical significance, highlight a major limitation to this study: 
the time period under study is limited to two discrete points in time. Hence these 
measurements represent discrete values that do not allow for precise tracing of 
the trend or slope of change over a period of time. The ability to discern the 
changes in CD4 and CD8 cell measurements taken at several time points over 
the period of study, for example taking a range of repeated measurements during 
pregnancy and early postpartum, would have facilitated more precise evidence of 
the role that these lymphocyte subsets play in PMTCT.  It is plausible that such a 
rigorous assay of lymphocyte subsets may better elucidate how physiological 
changes during pregnancy affect the prevalence and function of CD4 and CD8 
cells. CD8 cell levels have been reported to increase significantly during the 
period immediately preceding parturition (Juretic et al., 2004) and have been 
reported to play a role in increasing maternal resistance to the virus (Ibrahim et 
al., 2004; Detels et al., 1994), a function which may plausibly contribute to the 
reduction in PMTCT. Though finding from the present study did illustrate 
significant increases in CD8 cell counts, the study design did not permit the 
investigation of the association between this increase in CD8 and maternal 
resistance to HIV-1.   
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5.3 CONCLUSION 
The role that CD4 and CD8 lymphocytes play during parturition in pregnant HIV-
positive women remains unclear. The present study demonstrated that CD4 cell 
counts and CD8 cell counts undergo statistically significant changes from 3rd 
trimester to postpartum (~10 weeks). However, these changes seem not to 
represent any clinically significant change in maternal disease progression during 
this time period and were found not to be associated with PMTCT. 
 
Although HIV RNA levels have been shown to be a more statistically significant 
predictor of increased risk of PMTCT, in resource-limited settings, diagnosis is 
typically made clinically and sometimes with the use of antibody tests. A 
definitive understanding of the changes these lymphocyte subsets undergo, the 
role they play and the triggers that initiate these changes during the period 
immediately surrounding delivery may play a critical role in reducing intrapartum 
mother-to-child transmission, which accounts for approximately 50% of all MTCT 
transmission. This would facilitate better the development of antiretroviral 
regimens that target immune response and also better management of deliveries 
by pregnant HIV-positive mothers, particularly in the Sub-Saharan Africa setting 
where long-term antiretroviral therapy is not yet a feasible option for a majority of 
HIV infected pregnant mothers. 
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APPENDIX 1 STATA output for sample size calculations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample size calculation for mean change   Sample size calculation for mean 
in CD4 Count  change in CD8 Count 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. sampsi 388.75 537.25, sd1(152.9) sd2(275.96) 
 
Estimated sample size for two-sample comparison of means 
 
Test Ho: m1 = m2, where m1 is the mean in population 1 
                           and m2 is the mean in population 2 
Assumptions: 
 
         alpha =   0.0500  (two-sided) 
         power =   0.9000 
            m1 =   388.75 
            m2 =   537.25 
           sd1 =    152.9 
           sd2 =   275.96 
         n2/n1 =     1.00 
 
Estimated required sample sizes: 
 
            n1 =       48 
            n2 =       48 
sampsi 592.6 955.4, sd1(267.78) sd2(593.39) 
 
Estimated sample size for two-sample comparison of 
means 
 
Test Ho: m1 = m2, where m1 is the mean in population 1 
                                   and m2 is the mean in population 2 
Assumptions: 
 
         alpha =   0.0500  (two-sided) 
         power =   0.9000 
            m1 =    592.6 
            m2 =    955.4 
           sd1 =   267.78 
           sd2 =   593.39 
         n2/n1 =     1.00 
 
Estimated required sample sizes: 
 
            n1 =       34 
            n2 =       34 
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APPENDIX 2  A series of graphs illustrating the irregular distribution 
of CD8 cell counts 
. 
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APPENDIX 3  Results of Bivariate analysis of untransformed CD8 cell  
   counts. 
 
 
CD8 counts 
Non-Transmitting 
mothers, n (%) 
Transmitting 
mothers, n (%) 
Total 
Number 
3rdTrimestert    
<300 3 (1) 0 3 
300-650 61 (17.1) 4 (0.15) 65 
650-1000 130 (36.4) 11 (42.3) 141 
>1000 163 (45) 11 (42.3) 164 
Total 357 26 383 
Follow-up    
<300 2 (0.8) 0 (0.00) 2 
300-650 16 (6.4) 1 (5.88) 17 
650-1000 57 (22.8) 6 (28) 63 
>1000 175 (70) 14 (66.6) 189 
Total 250 21 271 
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APPENDIX 4 Scatterplot of change in maternal CD4 cell counts from  
   3rd trimester to postpartum by PMTCT. 
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Scatterplot of change in maternal CD4 cell counts from 3rd trimester to postpartum 
by PMTCT. [NB: Negative values represent an increase in CD4 count from 3rd trimester 
to postpartum (i.e. first follow-up CD4 counts larger than 3rd trimester CD4 counts)]  
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APPENDIX 5 Scatterplot of mean changes in maternal CD4 counts  
   from 3rd trimester to follow-up amongst groups mothers  
   categorized according to the week they returned for the  
   follow-up visit. 
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Scatterplot of mean changes in maternal CD4 counts from 3rd trimester to 
follow-up amongst groups mothers categorized according to the week they 
returned for the follow-up visit. [NB: Negative values represent an increase in CD4 
count from 3rd trimester to postpartum (i.e. first follow-up CD4 counts larger than 3rd 
trimester CD4 counts)]  
 
 
 
 
 
 
 
 
 
 
 
